IMS Consulting Group (IMSCG)

IMS Consulting Group (IMSCG) Company Profile

THE SCOOP 

Savvy specialists with global reach

IMS Consulting Group (IMSCG) is a major player in the field of global biotech and pharmaceutical management consulting. With around 500 consultants, the firm maintains a presence on five continents and focuses on partnering with clients in the pharmaceuticals, biotech and other life sciences sectors to help them make informed decisions. IMSCG has growing teams in the emerging markets, with strong local experts in Brazil, Shanghai, Singapore, and truly global project work offering teams broader exposure. 

The company has four main centers of excellence: brand and commercial strategy, competitive intelligence, pricing and market access, and strategy and portfolio analysis. Altogether, those units offer clients end-to-end services, qualitative and quantitative analysis of existing and emerging market trends and thorough implementation and execution of those strategies.

 

A healthy outlook

If the IMS name seems familiar in the life sciences context, that's probably because IMS Consulting Group is a unit of IMS Health-one of the best-known providers of information services for the healthcare industry. Having long offered consulting as a service, the firm decided in 2011 to create a separate identity for its management consulting arm-and IMS Consulting Group is the result.

In addition to partnering with some of the biggest names in pharmaceuticals and biotech, IMSCG consultants also help non-profit organizations to work towards their goals in designing and delivering solutions to some of the most pressing global health programs. One such example is IMSCG's involvement with the Bill and Melinda Gates foundation, which the firm advised on a program to improve access to generic medication.

 

IN THE NEWS 

IMS Consulting Group regularly produces research and white papers, which can be found by clicking here.

 

October and September 2013

Emerging Market Expertise

IMS Consulting vice-president Waseem Noor was quoted in two articles on the opportunities for Big Pharma firms in emerging markets. "Less than a decade ago, no company had a dedicated strategy for these markets," he said at a roundtable discussion with Pharma Exec, "It was all opportunistic and short-term, focused on a small elite segment of the local population. Today, you can't be a true pharma multinational if you aren't present in the emerging markets in a big way."

In October, meanwhile, he told Fierce Pharma that "We still see significant growth coming from these countries […] I think we see it's much harder to be successful in these countries than originally expected. To be an active player and a winning player is a completely different ballgame."

Read the full articles at Pharma Exec and Fierce Pharma.

 

May 2013

Pharma 50 article 

IMS Consulting Group's latest Pharma 50 article, published in the May edition of Pharmaceutical Executive magazine, ranked the top 50 pharma companies and described performance trends by geography. The firm found that although there may be declines in the industry in certain geographies, this downward trend is mostly driven by the performance of a handful of larger companies facing challenges like patent expiry of multi-billion dollar products. The article also showed where some interesting opportunities exist, and how some companies are adapting their business strategies and plans to take advantage of new market dynamics.

 

May 2013 

Study shows evidence-based drug reimbursement decisions

The Pink Sheet published a new study by IMS Health and IMS Consulting Group that shows payers globally are making more drug reimbursement decisions based on real-world evidence - including 25 percent of more than 100 identified case studies using biopharma industry-generated data.

The report, "RWE Market Impact on Medicines: A Lens for Pharma," was authored by Ben Hughes, senior principal of real-world evidence solutions at IMS, and Marla Kessler, VP and Europe region leader at IMS Consulting Group.

 

February 2013 

Parsing the German drug pricing law

IMSCG Principal Justus Dehnen was quoted in a Financial Times/BioPharm Insight article on the AMNOG assessment of DPP-4 inhibitors. The article states that Novartis has fair claim to challenge German drug pricing law, though a less compelling case to protect diabetes drugs.

Read the full article here.

▲ Show Less▼ Show Full Description


IMS Consulting Group (IMSCG)


485 Lexington Avenue
26th Floor
New York, NY 10017
Phone: 917-542-5800
Fax: 917-542-5801
www.imsconsultinggroup.com

STATS


  • Employer Type: Subsidiary
  • Stock Symbol: IMS
  • Stock Exchange: NYSE
  • President: Jose Luis Fernandez
  • 2014 Employees: 475

  • Employment Contact

    Visit IMS' careers page


  • Major Departments & Practices

    Brand & Commercial Strategy

    Competitive Intelligence

    Pricing & Market Access

    Strategy & Portfolio Analysis

Major Office Locations

  • New York, NY (HQ)
  • Deerfield, IL
  • Collegeville, PA
  • San Diego
  • San Francisco
  • Watertown, CT
  • Basel
  • Cambridge, U.K.
  • Istanbul
  • London
  • Madrid
  • Munich
  • Paris
  • Beijing
  • Seoul
  • Shanghai
  • Singapore
  • Tokyo
▲ Show Less▼ Show All

Become a Vault Basic Member

Complete your Vault Profile and get seen by top employers